Feature

Glucagon-Like Peptide-1 Receptor Agonist Use Before and After Liver Transplant

Abstract: Metabolic dysfunction, manifesting as obesity, type 2 diabetes mellitus (T2DM), and related cardiometabolic comorbidities, has emerged as a major driver of morbidity among patients with […]

Advances in IBS

What Is New in the Rome V Criteria for Disorders of Gut-Brain Interaction?

G&H How did the Rome Foundation choose the name of disorders of gut-brain interaction? Does this name assign too much emphasis to the brain? JT The […]

Clinical Update

Treating the Spectrum of Care in Esophageal Disease States: From Prevention to Palliation

G&H What is the role of a provider such as yourself in the management of patients with gastroesophageal reflux disease, Barrett esophagus, and esophageal cancer? KC […]

Advances in Hepatology

Workforce Issues in Hepatology

G&H Why is the burden of liver disease and complexity of care rising? SP One reason is that the risk of metabolic dysfunction-associated steatotic liver disease […]

Advances in IBD

Monitoring for Postoperative Recurrence of Crohn’s Disease

G&H Why is monitoring for postoperative recurrence of Crohn’s disease important? NKC The risk of postoperative recurrence of Crohn’s disease is incredibly high. Population-based studies have […]

Letter From the Editor

Letter From the Editor: Use of Glucagon-Like Peptide-1 Receptor Agonists Across the Liver Transplant Continuum

This month’s issue of Gastroenterology & Hepatology places a spotlight on the evolving role of glucagon-like peptide-1 receptor agonists (GLP-1RAs) before and after liver transplant (LT). […]